Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.
The authors found that buspirone added to the treatment of 33 patients with obsessive-compulsive disorder who were refractory to the serotonin reuptake inhibitor fluvoxamine was no better than placebo in reducing obsessive-compulsive, depressive, or anxiety symptoms. This finding suggests that addition of buspirone to ongoing fluvoxamine therapy is not an effective treatment strategy for most patients with obsessive-compulsive disorder.
McDougle
C J
CJ
Clinical Neuroscience Research Unit, Yale University School of Medicine, Connecticut Mental Health Center, New Haven 06519.
Goodman
W K
WK
Leckman
J F
JF
Holzer
J C
JC
Barr
L C
LC
McCance-Katz
E
E
Heninger
G R
GR
Price
L H
LH
D000328:Adult; D001008:Anxiety Disorders / Q000175:diagnosis / Q000523:psychology; D002065:Buspirone / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000175:diagnosis / Q000523:psychology; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D010919:Placebos; D011569:Psychiatric Status Rating Scales
D010919:Placebos; D016666:Fluvoxamine; D002065:Buspirone